In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following ...(ld watch for these as well as for anxiet...)

Date:1/18/2008

ld watch for these as well as for anxiety, agitation, panic, difficulty sleeping, irritability, hostility, aggressiveness, impulsivity, restlessness, or over excitement and hyperactivity. Call the doctor if any of these are severe or occur suddenly. Be especially observant at the initiation of antidepressant drug therapy and when there is a change in dose.

Tell your doctor if you have ever been told you had Bipolar Disorder ("Manic Depression") or have had a "manic" or "psychotic" episode.

For more information, including full Prescribing Information, please visit http://www.prozac.com, or call 1-800-LillyRX.

Prozac(R) is a registered trademark of Eli Lilly and Company. Prozac(R)Weekly(TM) is a trademark of Eli Lilly and Company. Sarafem(R) is a registered trademark of Warner Chilcott, Inc.

About Cymbalta

Important Safety Information

Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Cymbalta is approved only for adults 18 and over.

Cymbalta is not for everyone. Patients should not take Cymbalta if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine) or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have, including liver or kidney problems or glaucoma. Patients should tell their doctor about all of their medicines, including those for migraine to avoid a potentially life-threatening condition, and NSAIDs
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. CNS Response Announces Fiscal Third Quarter 2007 Results
2. Response Genetics Reports Second Quarter 2007 Financial Results
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
5. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
6. New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
9. Triage study challenges notions of emergency medical response to disaster
10. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.